您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (1): 1-5.doi: 10.6040/j.issn.1671-7554.0.2019.1037

• 基础医学 •    下一篇

重组人血管内皮抑素联合重组人干扰素γ对小鼠Lewis肺癌移植瘤的作用

徐鹏飞1,朱玲1,万云焱1,姚周虹1,李德志1,王聪2,翟聪聪3,李文4,林殿杰1   

  1. 1.山东大学附属省立医院呼吸与危重症医学科, 山东 济南 250021;2.盐城市第一人民医院呼吸与危重症医学科, 江苏 盐城 224000;3.山东大学齐鲁医院呼吸与危重症医学科, 山东 济南 250012;4.徐州第五干休所, 江苏 徐州 221000
  • 发布日期:2022-09-27
  • 通讯作者: 林殿杰. E-mail:lindianjie@126.com

Effects of recombinant human endostatin combined with recombinant human interferon γ on mouse Lewis lung cancer xenografts

XU Pengfei1, ZHU Ling1, WAN Yunyan1, YAO Zhouhong1, LI Dezhi1, WANG Cong2, ZHAI Congcong3, LI Wen4, LIN Dianjie1   

  1. 1. Department of Respiratory and critical care medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Respiratory and Critical Care Medicine, Yancheng No.1 People's Hospital, Yancheng 224000, Jiangsu, China;
    3. Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    4. Xuzhou No.5 Cadre's Sanatorium, Xuzhou 221000, Jiangsu, China
  • Published:2022-09-27

PDF (PC)

62

摘要： 目的 探讨重组人内皮抑素(Endostatin)联合重组人干扰素γ(IFNγ)对小鼠Lewis肺癌移植瘤的作用。 方法 建立小鼠Lewis肺癌移植瘤模型,分为对照组、Endostatin组、IFNγ组和Endostatin+IFNγ组(n均=10),对照组给予鼠磷酸盐缓冲盐水14 d,Endostatin组给予(Endostatin)15 mg/kg·d共14 d、IFNγ组给予(IFNγ)750 IU/kg·d共14 d、Endostatin(15 mg/kg·d)+IFNγ组(750 IU/kg·d)14 d,测量肿瘤的最长径和最短径,计算肿瘤体积。免疫组织化学法测定各组肿瘤组织微血管密度、血管内皮生长因子(VEGF)及低氧诱导因子-1α(HIF-1α)的表达,实时定量RT-PCR法检测VEGF、HIF-1α的表达。 结果 与对照组比较,Endostatin组、IFNγ组、Endostatin+IFNγ组显示出肿瘤抑制作用(P均<0.001),Endostatin+IFNγ组抑瘤作用最高(P<0.001);Endostatin组、IFNγ组、Endostatin+IFNγ组肿瘤微血管密度降低(P均<0.001),其中Endostatin+IFNγ组肿瘤微血管密度亦较Endostatin组、IFNγ组降低(P<0.001);Endostatin组、IFNγ组、Endostatin+IFNγ组VEGF表达降低(P<0.001),HIF-1α表达升高(P均<0.001),其中Endostatin+IFNγ组变化大(P<0.001)。 结论 Endostatin+IFNγ联合治疗可更有效地抑制肿瘤血管生成,并有效抑制肿瘤生长。

关键词: 血管内皮抑素, 干扰素γ, 肺癌, 血管生成

Abstract: Objective To investigate the effects of recombinant human endostatin(Endostatin)combined with recombinant human interferon γ(IFNγ)on Lewis lung cancer xenografts in mice. Methods Mice models of Lewis lung cancer xenografts were established and divided into control group, Endostatin group, IFNγ group, and Endostatin+IFNγ group, with 10 mice in each group. The control group was given phosphate buffered saline, Endostatin group was given 15 mg/(kg·d)endostatin, IFNγ group was given 750 IU/(kg·d)IFNγ, and Endostatin+IFNγ group was given 15 mg/(kg·d)endostatin and 750 IU/(kg·d)IFNγ. After 14 days of treatment, the longest and shortest diameters of tumor were measured to calculate tumor volume. The expressions of microvessel density, vascular endothelial growth factor(VEGF)and hypoxic inducible factor-1 α(HIF-1α)were detected with immunohisto chemistry. The expressions of VEGF and HIF-1α were determined with real-time quantitative RT-PCR. Results Compared with the control group, Endostatin, IFNγ and Endostatin+IFNγ groups showed obvious tumor inhibition(P<0.001), and Endostatin+IFNγ group had the most significant tumor inhibition effect(P<0.001). The microvessel density in Endostatin, IFNγ and 山 东 大 学 学 报 (医 学 版)58卷1期 -徐鹏飞,等.重组人血管内皮抑素联合重组人干扰素γ对小鼠Lewis肺癌移植瘤的作用 \=-Endostatin+IFNγ groups all significantly decreased(all P<0.001), and Endostatin+IFNγ group had the lowest density compared with Endostatin and IFNγ groups(P<0.001). The expression of VEGF in Endostatin, IFNγ and Endostatin+IFNγ groups all significantly decreased(P<0.001), while the expression of HIF-1α significantly increased(P<0.001), and the change in Endostatin+IFNγ group was the most significant(P<0.001). Conclusion Combination therapy of endostatin and IFNγ caneffectively inhibits tumor angiogenesis and tumor growth.

Key words: Endostatin, Interferon γ, Lung cancer, Angiogenesis

中图分类号: 

  • R734.2
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[3] Mencoboni M, Filiberti RA, Taveggia P, et al. Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine inelderly patients with NSCLC[J]. Anticancer Res, 2017, 37(6): 3189-3194.
[4] Ham M, Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression[J]. Arch Pharm Res, 2013, 36(12): 1419-1431.
[5] Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy[J]. Cancer Metastasis Rev, 2011, 30(1): 83-95.
[6] Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence oninterferonsignaling[J]. Cell, 2016, 165(2): 272-275.
[7] Yao D, Shen H, Huang J, et al. Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: a retrospective observational study [J]. Medicine, 2018, 97(32):e11822. doi:10.1097/MD.0000000000011822.
[8] 王聪,朱玲,万云焱,等. 重组人血管内皮抑制素不同给药途径联合顺铂对小鼠Lewis肺癌的疗效[J].山东大学学报(医学版), 2019, 57(5): 93-98. WANG Cong, ZHU Ling, WAN Yunyan, et al.Therapeutic effect of different administration ways of recombinant human endostatin combined with cisplatin on Lewis lung cancer xenografts in mice [J]. Journal of Shandong University(Health Sciences), 2019, 57(5): 93-98.
[9] Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment[J]. Front Oncol, 2016, 6: 66.doi: 10.3389/fonc.2016.00066.
[10] Chen X, Zhang H, Zhu H, et al. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer[J]. TumourBiol, 2016, 37(4): 4679-4688.
[11] Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis[J]. Cell, 2011, 146(6): 873-887.
[12] Ackermann M, Konerding MA. Vascular casting for the study of vascular morphogenesis[J]. Methods Mol Biol, 2015, 1214: 49-66.doi: 10.1007/978-1-4939-1462-3_5.
[13] Alahuhta I, Aikio M, Vayrynen O, et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment[J]. Exp Cell Res, 2015, 336(1): 130-140.
[14] Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models[J]. PLoS One, 2012, 7(4): e34646.doi: 10.1371/journal.pone.0034646.
[15] Wu Y, Meitzler JL, Antony S, et al. Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A[J]. Oncotarget, 2016, 7(42): 68412-68433.
[16] Laug R, Fehrholz M, Schütze N, et al. IFN-γ and TNF-α synergize to inhibit CTGF expression in human lung endothelial cells[J]. PLoS One, 2012, 7(9): e45430.doi: 10.1371/journal.pone.0045430.
[17] Liu X, Nie W, Xie Q, et al. Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma[J]. Oncol Lett, 2018, 15(2): 1874-1880.
[18] Jiang S, Wang G, Dong Y. Endostatin combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: a case report[J]. Medicine(Baltimore), 2017, 96(51): e9077.doi: 10.1097/MD.0000000000009077.
[19] Guset G, Costi S, Lazar E, et al. Expression of vascular endothelial growth factor(VEGF)and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma[J]. Rom J MorpholEmbryol, 2010, 51(4): 677-682.
[20] Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis[J]. Oncology, 2011, Suppl 1: 24-29. doi:10.1159/000333256.
[21] Liu ZJ, Semenza GL, Zhang HF. Hypoxia-inducible factor 1 and breast cancer metastasis[J]. J Zhejiang Univ Sci B, 2015, 16(1): 32-43.
[22] Ji R C. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis[J]. Cancer Lett, 2014, 346(1): 6-16.
[1] 于德新 蔡跃红 马祥兴 张晓明 李传福. 肝细胞癌血管生成及其成熟度的临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 51-54.
[2] 黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[3] 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[4] 杜艾家,张曼,陈鹤,王丽新,尚应殊. 微小RNA-1270靶向调控血管生成素样蛋白7抑制巨噬细胞炎症和脂质蓄积[J]. 山东大学学报 (医学版), 2025, 63(2): 1-9.
[5] 徐年兴,魏东,乔俊杰,战炳炎. CD8+、IL-6和PaO2对不可切除ⅢB/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[6] 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[7] 李懿原,马珊,李爱华,龙飞. 超声支气管镜引导下碘-125粒子植入治疗肺癌中央区淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(12): 26-34.
[8] 刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[9] 张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[10] 王亚楠,梁传杰,贾梦琪,苑辉卿. 二硫键异构酶TMX1促进肺癌化疗耐药[J]. 山东大学学报 (医学版), 2023, 61(8): 31-39.
[11] 王蕾,向淇,刘学伍. 伴系统性硬化症、类风湿关节炎的副肿瘤神经综合征1例[J]. 山东大学学报 (医学版), 2023, 61(7): 118-120.
[12] 钟璐,薛付忠. 基于贝叶斯网络不确定性推理的肺癌风险预测模型[J]. 山东大学学报 (医学版), 2023, 61(4): 86-94.
[13] 程传龙,韩闯,房启迪,刘盈,杨淑霞,崔峰,刘靖靖,李秀君. 基于时空地理加权回归模型探索肺癌发病的环境影响因素[J]. 山东大学学报 (医学版), 2023, 61(4): 95-102.
[14] 杨咏青,赵鹏,汪玉,马文静,田迷迷,程亚旎,祖璐,林祥涛. 细胞外容积分数对62例不同病理类型肺癌的诊断价值[J]. 山东大学学报 (医学版), 2023, 61(2): 88-94.
[15] 艾江山,高会江,艾仕文,李恒艳,石国栋,魏煜程. CT影像组学对囊腔型肺癌的诊断价值[J]. 山东大学学报 (医学版), 2023, 61(12): 70-77.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发